After EF reduction (<50%), HF treatment—ACE-inhibitors and beta-blockers, possibly in combination—was promptly initiated, and increased to the maximally tolerated dose in all patients of the cardioncological approach group. The gene discussed is ACE; the disease is hydrops fetalis.